RoosterBio & Repligen Collaborate to Advance Scalable Exosome Bioprocessing
RoosterBio, Inc. announced that it has selected Repligen Corporation, a life sciences company focused on bioprocessing technology leadership, as a collaboration partner to advance scalable exosome bioprocessing.
[89bio, Inc.] 89bio, Inc. announced positive topline data from the Phase IIb ENLIVEN trial evaluating treatment with pegozafermin in patients with NASH. In the study, both the 44mg Q2W and 30mg QW doses met, with high statistical significance.
[Communications Biology] The expression of myocardial infarction-associated transcript (MIAT) was up-regulated during liver fibrosis. Silencing MIAT led to the suppression of hepatic stellate cell proliferation and collagen expression.